emivirine
Small moleculeexperimental
Emivirine (MKC-442) is a failed experimental agent for the treatment of HIV. It is a non-nucleoside reverse transcriptase inhibitor. While emivirine showed promising antiviral activity in vitro, it failed to show sufficient efficacy in human trials. However it is still notable as an early proof of concept, which led to the discovery of a number of related antiviral drugs. — Wikipedia
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002215)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O- Mol. weight
- 302.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmivirine ↗
- ChEMBLCHEMBL35033 ↗
Also known as
- 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1h,3h)-dione
- 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2,4(1h,3h)-dione
- 2,4(1h,3h)-pyrimidinedione, 1-(ethoxymethyl)-5-(1-methylethyl)-6-(phenylmethyl)-
- 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil
- 6-benzyl-1-(ethoxymethyl)-5-(1-methylethyl)uracil
- 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil
- 6-benzyl-1-ethoxymethyl-5-isopropyluracil
- coactinon
- coactinon
- emivirine
- emivirine
- emivirine
- emivirine
- emivirine
- mkc 442
- mkc-442
- mkc-442
- mkc-442
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002215 | N/A | Nov 2, 1999 | Triangle Pharmaceuticals |
| NCT00002412 | Phase 2 | Nov 2, 1999 | Triangle Pharmaceuticals |
| NCT00002413 | Phase 2 | Nov 2, 1999 | Triangle Pharmaceuticals |
| NCT00002418 | Phase 2 | Nov 2, 1999 | Boehringer Ingelheim, Bristol-Myers Squibb, Triangle Pharmaceuticals |
| NCT00002420 | Phase 2 | Nov 2, 1999 | Bristol-Myers Squibb, Pharmacia & Upjohn, Triangle Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Triangle Pharmaceuticals | For profit | 5 | 3 | 2 | 1999 |
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 1999 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 1999 |
| Pharmacia & Upjohn | For profit | 1 | 0 | 1 | 1999 |
4 organizations
Page 1 / 1